Examining the prevalence of homologous recombination repair defects in ER+ breast cancers. Moore GM, Powell SN, Higginson DS, Khan AJ, et al. Breast Cancer Res Treat 2022;192:649-653.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Moore GM, Powell SN, Higginson DS, Khan AJ, et al. Examining the prevalence of homologous recombination repair defects in ER+ breast cancers. Breast Cancer Res Treat 2022;192:649-653.
PMID: 35092538